Lymphangioleiomyomatosis

Also known as: Lymphangiomyomatosis / Lymphangioleiomyomatoses

DrugDrug NameDrug Description
DB00877SirolimusA macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
DrugDrug NamePhaseStatusCount
DB01611Hydroxychloroquine1Completed1
DB00877Sirolimus1Completed1
DB01590Everolimus1 / 2Completed1
DB00619Imatinib1 / 2Not Yet Recruiting1
DB00641Simvastatin1 / 2Recruiting1
DB01590Everolimus2Completed1
DB01006Letrozole2Completed1
DB09079Nintedanib2Recruiting1
DB00104Octreotide2Completed1
DB02709Resveratrol2Not Yet Recruiting1
DB01001Salbutamol2Recruiting1
DB00877Sirolimus2Completed1
DB00877Sirolimus2Not Yet Recruiting1
DB00877Sirolimus2Unknown Status1
DB00877Sirolimus3Unknown Status1
DB00254Doxycycline4Completed1
DB01590EverolimusNot AvailableRecruiting1
DB00877SirolimusNot AvailableRecruiting1